# EDGAR Filing Document

**Accession Number:** 0000734383
**File Stem:** 0000734383-26-000210
**Filing Date:** 2026-6
**Character Count:** 65407
**Document Hash:** 701eb3b81496118c165ee0ea5e638be7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000734383-26-000210.hdr.sgml**: 20260626

**ACCESSION NUMBER**: 0000734383-26-000210

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260430

**FILED AS OF DATE**: 20260626

**DATE AS OF CHANGE**: 20260626

**PERIOD START**: 20270131

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VANGUARD SPECIALIZED FUNDS
- **CENTRAL INDEX KEY:** 0000734383

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0131

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-03916
- **FILM NUMBER:** 261128180

**BUSINESS ADDRESS:**
- **STREET 1:** PO BOX 2600
- **STREET 2:** V26
- **CITY:** VALLEY FORGE
- **STATE:** PA
- **ZIP:** 19482
- **BUSINESS PHONE:** 6106691000

**MAIL ADDRESS:**
- **STREET 1:** PO BOX 2600
- **STREET 2:** V26
- **CITY:** VALLEY FORGE
- **STATE:** PA
- **ZIP:** 19482

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VANGUARD SPECIALIZED FUNDS/
- **DATE OF NAME CHANGE:** 20011121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VANGUARD SPECIALIZED PORTFOLIOS INC
- **DATE OF NAME CHANGE:** 19920703

## Series and Classes Contracts Data

### Vanguard Health Care Fund (Series ID: S000002922)

| Class ID   | Class Name      | Ticker Symbol   |
|:---|:---|:---|
| C000008007 | Investor Shares | VGHCX           |
| C000008008 | Admiral Shares  | VGHAX           |

## Nport-Ex

Vanguard<sup>®</sup> Health Care Fund

#### Schedule of Investments (unaudited)
As of April 30, 2026

The fund files its complete schedule of portfolio holdings with the Securities and Exchange Commission (SEC) for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. The fund's Form N-PORT reports are available on the SEC's website at www.sec.gov.

---

| | | | |
|:---|:---|:---|:---|
|  |  | Shares | &nbsp;&nbsp;&nbsp;&nbsp;Market<br> Value<br> ($000) |
| **Common Stocks (97.9%)** | **Common Stocks (97.9%)** | **Common Stocks (97.9%)** | **Common Stocks (97.9%)** |
| **Belgium (3.9%)** | **Belgium (3.9%)** | **Belgium (3.9%)** | **Belgium (3.9%)** |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Argenx SE | 1008057 | &nbsp;&nbsp;&nbsp;&nbsp; 790546 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;UCB SA | 2355442 | &nbsp;&nbsp;&nbsp;&nbsp; 641367 |
|  |  |  | &nbsp;&nbsp;&nbsp;&nbsp; **1431913** |
| **China (1.1%)** | **China (1.1%)** | **China (1.1%)** | **China (1.1%)** |
| <sup>\*,1</sup> | &nbsp;&nbsp;&nbsp;GenFleet Therapeutics Shanghai Inc. Class H | 18491938 | &nbsp;&nbsp;&nbsp;&nbsp; 102853 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Duality Biotherapeutics Inc. | 2771377 | &nbsp;&nbsp;&nbsp;&nbsp; 98896 |
|  | &nbsp;&nbsp;&nbsp;Jiangsu Hengrui Pharmaceuticals Co. Ltd. Class H | 9939973 | &nbsp;&nbsp;&nbsp;&nbsp; 82882 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Zai Lab Ltd. | 36431700 | &nbsp;&nbsp;&nbsp;&nbsp; 78191 |
|  | &nbsp;&nbsp;&nbsp;Shandong Weigao Group Medical Polymer Co. Ltd. Class H | 77092000 | &nbsp;&nbsp;&nbsp;&nbsp; 33977 |
|  |  |  | &nbsp;&nbsp;&nbsp;&nbsp; **396799** |
| **Denmark (2.1%)** | **Denmark (2.1%)** | **Denmark (2.1%)** | **Denmark (2.1%)** |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Genmab A/S | 1345944 | &nbsp;&nbsp;&nbsp;&nbsp; 356374 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Ascendis Pharma A/S | 1022832 | &nbsp;&nbsp;&nbsp;&nbsp; 234617 |
|  | &nbsp;&nbsp;&nbsp;Novo Nordisk A/S Class B | 4131421 | &nbsp;&nbsp;&nbsp;&nbsp; 175734 |
|  |  |  | &nbsp;&nbsp;&nbsp;&nbsp; **766725** |
| **Japan (5.4%)** | **Japan (5.4%)** | **Japan (5.4%)** | **Japan (5.4%)** |
|  | &nbsp;&nbsp;&nbsp;Chugai Pharmaceutical Co. Ltd. | 8606142 | &nbsp;&nbsp;&nbsp;&nbsp; 458960 |
|  | &nbsp;&nbsp;&nbsp;Otsuka Holdings Co. Ltd. | 5806600 | &nbsp;&nbsp;&nbsp;&nbsp; 423197 |
|  | &nbsp;&nbsp;&nbsp;Shionogi & Co. Ltd. | 20439649 | &nbsp;&nbsp;&nbsp;&nbsp; 412941 |
|  | &nbsp;&nbsp;&nbsp;Daiichi Sankyo Co. Ltd. | 22675166 | &nbsp;&nbsp;&nbsp;&nbsp; 368337 |
|  | &nbsp;&nbsp;&nbsp;Eisai Co. Ltd. | 7339417 | &nbsp;&nbsp;&nbsp;&nbsp; 219687 |
|  | &nbsp;&nbsp;&nbsp;M3 Inc. | 9451653 | &nbsp;&nbsp;&nbsp;&nbsp; 91043 |
|  |  |  | &nbsp;&nbsp;&nbsp;&nbsp; **1974165** |
| **Switzerland (4.1%)** | **Switzerland (4.1%)** | **Switzerland (4.1%)** | **Switzerland (4.1%)** |
|  | &nbsp;&nbsp;&nbsp;Novartis AG (Registered) | 4043167 | &nbsp;&nbsp;&nbsp;&nbsp; 597539 |
|  | &nbsp;&nbsp;&nbsp;Galderma Group AG | 2228631 | &nbsp;&nbsp;&nbsp;&nbsp; 467552 |
|  | &nbsp;&nbsp;&nbsp;Roche Holding AG | 1122465 | &nbsp;&nbsp;&nbsp;&nbsp; 457404 |
|  |  |  | &nbsp;&nbsp;&nbsp;&nbsp; **1522495** |
| **United Kingdom (8.5%)** | **United Kingdom (8.5%)** | **United Kingdom (8.5%)** | **United Kingdom (8.5%)** |
|  | &nbsp;&nbsp;&nbsp;AstraZeneca plc | 9897175 | &nbsp;&nbsp;&nbsp;&nbsp; 1877714 |
|  | &nbsp;&nbsp;&nbsp;GSK plc | 44002585 | &nbsp;&nbsp;&nbsp;&nbsp; 1153636 |
| <sup>\*,1,2</sup> | &nbsp;&nbsp;&nbsp;Immunocore Holdings plc ADR | 4246274 | &nbsp;&nbsp;&nbsp;&nbsp; 118514 |
|  |  |  | &nbsp;&nbsp;&nbsp;&nbsp; **3149864** |
| **United States (72.8%)** | **United States (72.8%)** | **United States (72.8%)** | **United States (72.8%)** |
|  | &nbsp;&nbsp;&nbsp;Eli Lilly & Co. | 3441601 | &nbsp;&nbsp;&nbsp;&nbsp; 3216520 |
|  | &nbsp;&nbsp;&nbsp;Merck & Co. Inc. | 18609420 | &nbsp;&nbsp;&nbsp;&nbsp; 2031777 |
|  | &nbsp;&nbsp;&nbsp;UnitedHealth Group Inc. | 3895307 | &nbsp;&nbsp;&nbsp;&nbsp; 1443133 |
|  | &nbsp;&nbsp;&nbsp;Johnson & Johnson | 5527324 | &nbsp;&nbsp;&nbsp;&nbsp; 1270455 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Edwards Lifesciences Corp. | 14158652 | &nbsp;&nbsp;&nbsp;&nbsp; 1182247 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Intuitive Surgical Inc. | 2186666 | &nbsp;&nbsp;&nbsp;&nbsp; 1000640 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Boston Scientific Corp. | 15070438 | &nbsp;&nbsp;&nbsp;&nbsp; 868208 |
|  | &nbsp;&nbsp;&nbsp;Danaher Corp. | 4836473 | &nbsp;&nbsp;&nbsp;&nbsp; 865487 |
|  | &nbsp;&nbsp;&nbsp;CVS Health Corp. | 9756578 | &nbsp;&nbsp;&nbsp;&nbsp; 812625 |
|  | &nbsp;&nbsp;&nbsp;Abbott Laboratories | 8842005 | &nbsp;&nbsp;&nbsp;&nbsp; 802766 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Vertex Pharmaceuticals Inc. | 1801919 | &nbsp;&nbsp;&nbsp;&nbsp; 770104 |
|  | &nbsp;&nbsp;&nbsp;Cencora Inc. | 2484451 | &nbsp;&nbsp;&nbsp;&nbsp; 765236 |
|  | &nbsp;&nbsp;&nbsp;Elevance Health Inc. (XNYS) | 1858361 | &nbsp;&nbsp;&nbsp;&nbsp; 699524 |
|  | &nbsp;&nbsp;&nbsp;Regeneron Pharmaceuticals Inc. | &nbsp;&nbsp;&nbsp;&nbsp;931886 | &nbsp;&nbsp;&nbsp;&nbsp; 658899 |
|  | &nbsp;&nbsp;&nbsp;HCA Healthcare Inc. | 1203410 | &nbsp;&nbsp;&nbsp;&nbsp; 522822 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Alnylam Pharmaceuticals Inc. | 1670679 | &nbsp;&nbsp;&nbsp;&nbsp; 517058 |
|  | &nbsp;&nbsp;&nbsp;AbbVie Inc. | 2356112 | &nbsp;&nbsp;&nbsp;&nbsp; 497894 |
|  | &nbsp;&nbsp;&nbsp;Cardinal Health Inc. | 2511651 | &nbsp;&nbsp;&nbsp;&nbsp; 484447 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Biogen Inc. | 2526097 | &nbsp;&nbsp;&nbsp;&nbsp; 478140 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;United Therapeutics Corp. | &nbsp;&nbsp;&nbsp;&nbsp;822896 | &nbsp;&nbsp;&nbsp;&nbsp; 470162 |
|  | &nbsp;&nbsp;&nbsp;Agilent Technologies Inc. | 3824222 | &nbsp;&nbsp;&nbsp;&nbsp; 441889 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Dexcom Inc. | 6365180 | &nbsp;&nbsp;&nbsp;&nbsp; 379047 |
|  | &nbsp;&nbsp;&nbsp;Thermo Fisher Scientific Inc. | &nbsp;&nbsp;&nbsp;&nbsp;745695 | &nbsp;&nbsp;&nbsp;&nbsp; 357158 |

---

------

---

| | | | |
|:---|:---|:---|:---|
|  |  | Shares | &nbsp;&nbsp;&nbsp;&nbsp;Market<br> Value<br> ($000) |
|  | &nbsp;&nbsp;&nbsp;Medtronic plc | 4228128 | &nbsp;&nbsp;&nbsp;&nbsp; 342352 |
|  | &nbsp;&nbsp;&nbsp;Stryker Corp. | &nbsp;&nbsp;&nbsp;&nbsp;970510 | &nbsp;&nbsp;&nbsp;&nbsp; 305837 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Ionis Pharmaceuticals Inc. | 3803181 | &nbsp;&nbsp;&nbsp;&nbsp; 284326 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Revolution Medicines Inc. | 1838404 | &nbsp;&nbsp;&nbsp;&nbsp; 264951 |
|  | &nbsp;&nbsp;&nbsp;STERIS plc | 1092821 | &nbsp;&nbsp;&nbsp;&nbsp; 237011 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Incyte Corp. | 2365620 | &nbsp;&nbsp;&nbsp;&nbsp; 225373 |
|  | &nbsp;&nbsp;&nbsp;QIAGEN NV | 6514443 | &nbsp;&nbsp;&nbsp;&nbsp; 225269 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Madrigal Pharmaceuticals Inc. | &nbsp;&nbsp;&nbsp;&nbsp;408918 | &nbsp;&nbsp;&nbsp;&nbsp; 211570 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Cytokinetics Inc. | 3197893 | &nbsp;&nbsp;&nbsp;&nbsp; 204569 |
|  | &nbsp;&nbsp;&nbsp;Bristol-Myers Squibb Co. | 3063693 | &nbsp;&nbsp;&nbsp;&nbsp; 185629 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;ICON plc | 1538110 | &nbsp;&nbsp;&nbsp;&nbsp; 182005 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;CG oncology Inc. | 2589248 | &nbsp;&nbsp;&nbsp;&nbsp; 172806 |
| <sup>\*,1,2</sup> | &nbsp;&nbsp;&nbsp;HeartFlow Inc. | 5663321 | &nbsp;&nbsp;&nbsp;&nbsp; 168540 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Scholar Rock Holding Corp. | 3466533 | &nbsp;&nbsp;&nbsp;&nbsp; 161575 |
|  | &nbsp;&nbsp;&nbsp;Encompass Health Corp. | 1600016 | &nbsp;&nbsp;&nbsp;&nbsp; 160002 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Vaxcyte Inc. | 2667349 | &nbsp;&nbsp;&nbsp;&nbsp; 152679 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Avantor Inc. | 18280648 | &nbsp;&nbsp;&nbsp;&nbsp; 148073 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Option Care Health Inc. | 7278969 | &nbsp;&nbsp;&nbsp;&nbsp; 147981 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Kymera Therapeutics Inc. | 1796469 | &nbsp;&nbsp;&nbsp;&nbsp; 145640 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Xenon Pharmaceuticals Inc. | 2569786 | &nbsp;&nbsp;&nbsp;&nbsp; 144011 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Alignment Healthcare Inc. | 6287140 | &nbsp;&nbsp;&nbsp;&nbsp; 141712 |
| <sup>\*,1</sup> | &nbsp;&nbsp;&nbsp;Celldex Therapeutics Inc. | 4279485 | &nbsp;&nbsp;&nbsp;&nbsp; 140709 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Protagonist Therapeutics Inc. | 1380445 | &nbsp;&nbsp;&nbsp;&nbsp; 136623 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Crinetics Pharmaceuticals Inc. | 3494255 | &nbsp;&nbsp;&nbsp;&nbsp; 135507 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;PTC Therapeutics Inc. | 2038232 | &nbsp;&nbsp;&nbsp;&nbsp; 132607 |
| <sup>\*,1</sup> | &nbsp;&nbsp;&nbsp;Acadia Healthcare Co. Inc. | 5021479 | &nbsp;&nbsp;&nbsp;&nbsp; 130031 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Apogee Therapeutics Inc. | 1490737 | &nbsp;&nbsp;&nbsp;&nbsp; 123567 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Structure Therapeutics Inc. ADR | 2909218 | &nbsp;&nbsp;&nbsp;&nbsp; 120587 |
| <sup>\*,1</sup> | &nbsp;&nbsp;&nbsp;Inspire Medical Systems Inc. | 2093826 | &nbsp;&nbsp;&nbsp;&nbsp; 117547 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Dianthus Therapeutics Inc. | 1244555 | &nbsp;&nbsp;&nbsp;&nbsp; 109272 |
| <sup>\*,2</sup> | &nbsp;&nbsp;&nbsp;Newamsterdam Pharma Co. NV | 3425823 | &nbsp;&nbsp;&nbsp;&nbsp; 97842 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Moderna Inc. | 1995366 | &nbsp;&nbsp;&nbsp;&nbsp; 91667 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Arcus Biosciences Inc. | 3445827 | &nbsp;&nbsp;&nbsp;&nbsp; 87869 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Nuvalent Inc. Class A | &nbsp;&nbsp;&nbsp;&nbsp;873258 | &nbsp;&nbsp;&nbsp;&nbsp; 87570 |
|  | &nbsp;&nbsp;&nbsp;Bio-Techne Corp. | 1500524 | &nbsp;&nbsp;&nbsp;&nbsp; 83009 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Natera Inc. | &nbsp;&nbsp;&nbsp;&nbsp;382952 | &nbsp;&nbsp;&nbsp;&nbsp; 78949 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Centene Corp. | 1363754 | &nbsp;&nbsp;&nbsp;&nbsp; 73220 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Bridgebio Pharma Inc. | &nbsp;&nbsp;&nbsp;&nbsp;982977 | &nbsp;&nbsp;&nbsp;&nbsp; 69900 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Immunome Inc. | 2776580 | &nbsp;&nbsp;&nbsp;&nbsp; 63695 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Stoke Therapeutics Inc. | 1652492 | &nbsp;&nbsp;&nbsp;&nbsp; 54070 |
| <sup>\*,2</sup> | &nbsp;&nbsp;&nbsp;Kailera Therapeutics Inc. | 2138327 | &nbsp;&nbsp;&nbsp;&nbsp; 53458 |
| <sup>\*</sup> | &nbsp;&nbsp;&nbsp;Mineralys Therapeutics Inc. | 1858489 | &nbsp;&nbsp;&nbsp;&nbsp; 49529 |
| <sup>\*,2</sup> | &nbsp;&nbsp;&nbsp;Aktis Oncology Inc. | 2023644 | &nbsp;&nbsp;&nbsp;&nbsp; 37943 |
|  |  |  | &nbsp;&nbsp;&nbsp;&nbsp;**26823320** |
| **Total Common Stocks (Cost $22,978,454)** | **Total Common Stocks (Cost $22,978,454)** | **Total Common Stocks (Cost $22,978,454)** | &nbsp;&nbsp;&nbsp;&nbsp;**36065281** |
| **Temporary Cash Investments (1.3%)** | **Temporary Cash Investments (1.3%)** | **Temporary Cash Investments (1.3%)** | **Temporary Cash Investments (1.3%)** |
| **Money Market Fund (0.1%)** | **Money Market Fund (0.1%)** | **Money Market Fund (0.1%)** | **Money Market Fund (0.1%)** |
| <sup>3,4</sup> | &nbsp;&nbsp;&nbsp;Vanguard Market Liquidity Fund, 3.685% | &nbsp;&nbsp;&nbsp;&nbsp;338258 | &nbsp;&nbsp;&nbsp;&nbsp; 33822 |
|  |  | Face<br> Amount<br> ($000) |  |
| **Repurchase Agreements (1.2%)** | **Repurchase Agreements (1.2%)** | **Repurchase Agreements (1.2%)** | **Repurchase Agreements (1.2%)** |
|  | &nbsp;&nbsp;&nbsp;Bank of America Securities, LLC, 3.650%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $31,103, collateralized by U.S. Government Agency Obligations 3.000%–5.500%, 11/1/2046–4/20/2056, with a value of $31,722) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31100 | &nbsp;&nbsp;&nbsp;&nbsp; 31100 |
|  | &nbsp;&nbsp;&nbsp;Bank of America Securities, LLC, 3.650%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $39,004, collateralized by U.S. Treasury Obligations 0.000%–4.000%, 7/9/2026–8/31/2032, with a value of $39,780) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;39000 | &nbsp;&nbsp;&nbsp;&nbsp; 39000 |
|  | &nbsp;&nbsp;&nbsp;Bank of America Securities, LLC, 3.660%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $25,003, collateralized by U.S. Government Agency Obligations 5.000%–5.500%, 11/1/2054–12/1/2055, with a value of $25,501) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25000 | &nbsp;&nbsp;&nbsp;&nbsp; 25000 |
|  | &nbsp;&nbsp;&nbsp;Bank of Nova Scotia, 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $34,303, collateralized by U.S. Treasury Obligations 0.750%–4.375%, 11/30/2026–8/15/2031, with a value of $34,990) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34300 | &nbsp;&nbsp;&nbsp;&nbsp; 34300 |
|  | &nbsp;&nbsp;&nbsp;Barclays Capital Inc., 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $37,204, collateralized by U.S. Treasury Obligations 3.750%, 5/15/2028, with a value of $37,944) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37200 | &nbsp;&nbsp;&nbsp;&nbsp; 37200 |

---

------

---

| | | |
|:---|:---|:---|
|  | Face<br> Amount<br> ($000) | &nbsp;&nbsp;&nbsp;&nbsp;Market<br> Value<br> ($000) |
| &nbsp;&nbsp;&nbsp;BNP Paribas Securities Corp., 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $30,003, collateralized by U.S. Treasury Obligations 0.000%–4.750%, 7/31/2026–2/15/2056, with a value of $30,600) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30000 | &nbsp;&nbsp;&nbsp;&nbsp; 30000 |
| &nbsp;&nbsp;&nbsp;BNP Paribas Securities Corp., 3.650%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $34,203, collateralized by U.S. Treasury and Government Agency Obligations 0.000%–6.500%, 12/31/2028–1/1/2056, with a value of $34,884) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34200 | &nbsp;&nbsp;&nbsp;&nbsp; 34200 |
| &nbsp;&nbsp;&nbsp;Credit Agricole Securities, 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $21,502, collateralized by U.S. Treasury and Government Agency Obligations 0.125%–5.800%, 10/15/2026–2/15/2054, with a value of $21,930) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21500 | &nbsp;&nbsp;&nbsp;&nbsp; 21500 |
| &nbsp;&nbsp;&nbsp;HSBC Bank USA, 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $80,508, collateralized by U.S. Treasury Obligations 0.625%–4.250%, 3/31/2033–8/15/2048, with a value of $82,110) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;80500 | &nbsp;&nbsp;&nbsp;&nbsp; 80500 |
| &nbsp;&nbsp;&nbsp;HSBC Bank USA, 3.650%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $9,401, collateralized by U.S. Government Agency Obligations 2.000%–7.000%, 8/1/2052–2/1/2056, with a value of $9,588) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9400 | &nbsp;&nbsp;&nbsp;&nbsp; 9400 |
| &nbsp;&nbsp;&nbsp;JP Morgan Securities, LLC, 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $29,003, collateralized by U.S. Treasury Obligations 0.000%–3.875%, 10/29/2026–12/31/2027, with a value of $29,580) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29000 | &nbsp;&nbsp;&nbsp;&nbsp; 29000 |
| &nbsp;&nbsp;&nbsp;Natixis SA, 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $17,302, collateralized by U.S. Treasury and Government Agency Obligations 0.125%–2.875%, 7/15/2026–11/10/2045, with a value of $17,646) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17300 | &nbsp;&nbsp;&nbsp;&nbsp; 17300 |
| &nbsp;&nbsp;&nbsp;Nomura International plc, 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $25,003, collateralized by U.S. Treasury Obligations 0.000%–4.250%, 7/9/2026–5/15/2048, with a value of $25,537) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25000 | &nbsp;&nbsp;&nbsp;&nbsp; 25000 |
| &nbsp;&nbsp;&nbsp;Nomura International plc, 3.640%, 5/1/2026<br> (Dated 4/30/2026, Repurchase Value $39,004, collateralized by U.S. Treasury Obligations 0.750%–4.250%, 10/31/2026–8/15/2035, with a value of $39,780) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;39000 | &nbsp;&nbsp;&nbsp;&nbsp; 39000 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp; **452500** |
| **Total Temporary Cash Investments (Cost $486,322)** | **Total Temporary Cash Investments (Cost $486,322)** | &nbsp;&nbsp;&nbsp;&nbsp;**486322** |
| **Total Investments (99.2%) (Cost $23,464,776)** | **Total Investments (99.2%) (Cost $23,464,776)** | &nbsp;&nbsp;&nbsp;&nbsp;**36551603** |
| **Other Assets and Liabilities—Net (0.8%)** | **Other Assets and Liabilities—Net (0.8%)** | &nbsp;&nbsp;&nbsp;&nbsp;**292589** |
| **Net Assets (100%)** | **Net Assets (100%)** | &nbsp;&nbsp;&nbsp;&nbsp;**36844192** |
| Cost is in $000. | Cost is in $000. | Cost is in $000. |

---

---

| | |
|:---|:---|
| \* | Non-income-producing security. |
| 1 | Considered an affiliated company of the fund as the fund owns more than 5% of the outstanding voting securities of such company. |
| 2 | Includes partial security positions on loan to broker-dealers. The total value of securities on loan is $31,627. |
| 3 | Affiliated money market fund available only to Vanguard funds and certain trusts and accounts managed by Vanguard. Rate shown is the 7-day yield. |
| 4 | Collateral of $33,027 was received for securities on loan. |
|  | ADR—American Depositary Receipt. |

---

**A.** Security Valuation: Securities are valued as of the close of trading on the New York Stock Exchange (generally 4 p.m., Eastern time) on the valuation date. Equity securities are valued at the latest quoted sales
prices or official closing prices taken from the primary market in which each security trades; such securities not traded on the valuation date are valued at the mean of the latest quoted bid and asked prices.
Securities for which market quotations are not readily available, or whose values have been affected by events occurring before the fund's pricing time but after the close of the securities' primary
markets, are valued by methods deemed by the valuation designee to represent fair value and subject to oversight by the board of trustees. These procedures include obtaining quotations from an independent pricing
service, monitoring news to identify significant market- or security-specific events, and evaluating changes in the values of foreign market proxies (for example, ADRs, futures contracts, or exchange-traded funds),
between the time the foreign markets close and the fund's pricing time. When fair-value pricing is employed, the prices of securities used by a fund to calculate its net asset value may differ from quoted or
published prices for the same securities. Investments in Vanguard Market Liquidity Fund are valued at that fund's net asset value. Other temporary cash investments are valued using the latest bid prices or using
valuations based on a matrix system (which considers such factors as security prices, yields, maturities, and ratings), both as furnished by independent pricing services.

**B.** Foreign Currency: Securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates obtained from an independent third party as of the fund's
pricing time on the valuation date. Realized gains (losses) and unrealized appreciation (depreciation) on investment securities include the effects of changes in exchange rates since the securities were purchased,
combined with the effects of changes in security prices. Fluctuations in the value of other assets and liabilities resulting from changes in exchange rates are recorded as unrealized foreign currency gains (losses)
until the assets or liabilities are settled in cash, at which time they are recorded as realized foreign currency gains (losses).

**C.** Repurchase Agreements: The fund enters into repurchase agreements with institutional counterparties. Securities pledged as collateral to the fund under repurchase agreements are held
by a custodian bank until the agreements mature, and in the absence of a default, such collateral cannot be repledged, resold, or rehypothecated. Each agreement requires that the market value of the collateral be
sufficient to cover payments of interest and principal. The fund further mitigates its counterparty risk by entering into repurchase agreements only with a diverse group of prequalified counterparties, monitoring
their financial strength, and entering into master repurchase agreements with its counterparties. The master repurchase agreements provide that, in the event of a counterparty's default (including bankruptcy), the
fund may terminate any repurchase agreements with that counterparty, determine the net amount owed, and sell or retain the collateral up to the net amount owed to the fund. Such action may be subject to legal
proceedings, which may delay or limit the disposition of collateral.

------

**D.** Various inputs may be used to determine the value of the fund's investments. These inputs are summarized in three broad levels for financial statement purposes. The inputs or methodologies used to value
securities are not necessarily an indication of the risk associated with investing in those securities.

#### Level 1 —Quoted prices in active markets for identical securities.

#### Level 2 —Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
**Level 3—Significant unobservable inputs (including the fund's own assumptions used to determine the fair value of investments). Any investments valued with significant unobservable inputs are noted on the Schedule of Investments.**

The following table summarizes the market value of the fund's investments as of April 30, 2026, based on the inputs used to value them:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Level 1<br> ($000) | &nbsp;&nbsp;&nbsp;Level 2<br> ($000) | &nbsp;&nbsp;&nbsp;Level 3<br> ($000) | &nbsp;&nbsp;&nbsp;Total<br> ($000) |
| **Investments** |  |  |  |  |
| Assets |  |  |  |  |
| Common Stocks—North and South America | 26823320 | &nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;26823320 |
| Common Stocks—Other | 353131 | &nbsp;&nbsp;&nbsp;8888830 | &nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;9241961 |
| Temporary Cash Investments | 33822 | &nbsp;&nbsp;&nbsp;452500 | &nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;486322 |
| Total | 27210273 | &nbsp;&nbsp;&nbsp;9341330 | &nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;36551603 |

---

**E.** Certain of the fund's investments are in companies that are considered to be affiliated companies of the fund because the fund owns more than 5% of the outstanding voting securities of the company or the
issuer is another member of The Vanguard Group. Transactions during the period in securities of these companies were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | Current Period Transactions | Current Period Transactions | Current Period Transactions | Current Period Transactions | Current Period Transactions | Current Period Transactions |  |
|  | Jan. 31,<br> 2026<br> Market<br> Value<br> ($000) | Purchases<br> at Cost<br> ($000) | Proceeds<br> from<br> Securities<br> Sold<br> ($000) | Realized<br> Net<br> Gain<br> (Loss)<br> ($000) | Change in<br> Unrealized<br> App. (Dep.)<br> ($000) | Income<br> ($000) | Capital Gain<br> Distributions<br> Received<br> ($000) | Apr. 30,<br> 2026<br> Market<br> Value<br> ($000) |
| Acadia Healthcare Co. Inc. | 118483 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;93305 | (169107) | 273960 |  |  | 130031 |
| Apellis Pharmaceuticals Inc. | 172343 | &nbsp;&nbsp;&nbsp;18957 | 350318 | &nbsp;&nbsp;171666 | &nbsp;&nbsp;(12648) |  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— |
| Celldex Therapeutics Inc. | 117212 | &nbsp;&nbsp;&nbsp;&nbsp;2428 | &nbsp;&nbsp;&nbsp;17659 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4107 | &nbsp;&nbsp;&nbsp;34621 |  |  | 140709 |
| GenFleet Therapeutics Shanghai Inc. Class H | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NA<sup>1</sup> | &nbsp;&nbsp;&nbsp;60435 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;34625 |  |  | 102853 |
| HeartFlow Inc. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NA<sup>1</sup> | &nbsp;&nbsp;&nbsp;95228 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;&nbsp;5909 |  |  | 168540 |
| Immunocore Holdings plc ADR | 119062 | &nbsp;&nbsp;&nbsp;18716 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;(19264) |  |  | 118514 |
| Inspire Medical Systems Inc. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NA<sup>1</sup> | &nbsp;&nbsp;&nbsp;60499 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;(25857) |  |  | 117547 |
| Vanguard Market Liquidity Fund | &nbsp;&nbsp;58780 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NA<sup>2</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NA<sup>2</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— |  |  | &nbsp;&nbsp;&nbsp;33822 |
| Total | 585880 | 256263 | 461282 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6665 | 291346 |  |  | 812016 |

---

1 Not applicable—at January 31, 2026, the issuer was not an affiliated company of the fund. <br> 2 Not applicable—purchases and sales are for temporary cash investment purposes.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** VANGUARD SPECIALIZED FUNDS

- **b. Investment Company Act file number:** 811-03916

- **c. CIK number of Registrant:** 0000734383

- **d. LEI of Registrant:** 549300OM0CLBHZ9MZW59

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 100 Vanguard Boulevard

  - **City:** Malvern

  - **State:** PA

  - **Foreign country:** US

  - **Zip / Postal Code:** 19355

  - **Telephone number:** 610-669-1000

**Item A.2. Information about the Series.**

- **a. Name of Series:** VANGUARD HEALTH CARE FUND

- **b. EDGAR series identifier (if any):** S000002922

- **c. LEI of Series:** V3VSQJG5SDM3YTFC5I04

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2027-01-31

- **b. Date as of which information is reported:** 2026-04-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $36897259450.68

**Total Liabilities:** $36259889.62

**Net Assets:** $36860999561.06

**Cash Not Reported:** $3033538.13

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000008007 | 3.12%                | -6.03%               | 0.02%                |
| Class ID C000008008 | 3.12%                | -6.02%               | 0.01%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $430328875.25            | $736576964.64                              |
| Month 2  | $203179610.02            | $-2707300306.29                            |
| Month 3  | $513406875.11            | $-512390357.82                             |

### Schedule of Portfolio Investments

| Name                                              | Title                                            | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)    | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Abbott Laboratories                               | ABBOTT LABS                                      | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |   8842005 | NS      | $802765633.95  | 2.18%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                                        | ABBVIE INC                                       | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |   2356112 | NS      | $497893587.84  | 1.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Acadia Healthcare Co Inc                          | ACADIA HEALTHCAR                                 | CUSIP: 00404A109<br>LEI: 5493005CW985Y9D0NC11 | Long             | EC               | CORP              | US        |   5021479 | NS      | $130031198.71  | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Agilent Technologies Inc                          | AGILENT TECH INC                                 | CUSIP: 00846U101<br>LEI: QUIX8Y7A2WP0XRMW7G29 | Long             | EC               | CORP              | US        |   3824222 | NS      | $441888852.10  | 1.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Aktis Oncology Inc                                | AKTIS ONCOLOGY I                                 | CUSIP: 01021M104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2023644 | NS      | $37943325.00   | 0.10%             |  |  |  | No            |                  1 | On Loan: —       |
| Alignment Healthcare Inc                          | ALIGNMENT HEALTH                                 | CUSIP: 01625V104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   6287140 | NS      | $141712135.60  | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc                       | ALNYLAM PHARMACE                                 | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |   1670679 | NS      | $517058443.71  | 1.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Cencora Inc                                       | CENCORA INC                                      | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |   2484451 | NS      | $765235752.51  | 2.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Elevance Health Inc                               | ELEVANCE HEALTH                                  | CUSIP: 036752103<br>LEI: 8MYN82XMYQH89CTMTH67 | Long             | EC               | CORP              | US        |   1858361 | NS      | $699524247.62  | 1.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Apogee Therapeutics Inc                           | APOGEE THERAPEUT                                 | CUSIP: 03770N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1490737 | NS      | $123567189.93  | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcus Biosciences Inc                             | ARCUS BIOSCIENCE                                 | CUSIP: 03969F109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   3445827 | NS      | $87868588.50   | 0.24%             |  |  |  | No            |                  1 | On Loan: No      |
| Avantor Inc                                       | AVANTOR INC                                      | CUSIP: 05352A100<br>LEI: 5493003VM0XB4U8YD238 | Long             | EC               | CORP              | US        |  20480758 | NS      | $165894139.80  | 0.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc                                        | BIOGEN INC                                       | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |   2526097 | NS      | $478139640.16  | 1.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                                   | BIO-TECHNE CORP                                  | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |   1825455 | NS      | $100984170.60  | 0.27%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                                   | ASTRAZENECA PLC                                  | CUSIP: N/A<br>LEI: PY6ZZQWO2IZFZC3IOL08       | Long             | EC               | CORP              | GB        |   9897175 | NS      | $1877713911.27 | 5.09%             |  |  |  | No            |                  2 | On Loan: No      |
| Boston Scientific Corp                            | BOSTON SCIENTIFC                                 | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |  15070438 | NS      | $868207933.18  | 2.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc                              | BRIDGEBIO PHARMA                                 | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |    982977 | NS      | $69899494.47   | 0.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co                           | BRISTOL-MYER SQB                                 | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |   3661639 | NS      | $221858707.01  | 0.60%             |  |  |  | No            |                  1 | On Loan: No      |
| CVS Health Corp                                   | CVS HEALTH CORP                                  | CUSIP: 126650100<br>LEI: 549300EJG376EN5NQE29 | Long             | EC               | CORP              | US        |   9756578 | NS      | $812625381.62  | 2.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Cardinal Health Inc                               | CARDINAL HEALTH                                  | CUSIP: 14149Y108<br>LEI: CCU46N3GJMF4OK4N7U60 | Long             | EC               | CORP              | US        |   2317298 | NS      | $446960438.24  | 1.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Celldex Therapeutics Inc                          | CELLDEX THERAPEU                                 | CUSIP: 15117B202<br>LEI: 529900F018DMYWH38923 | Long             | EC               | CORP              | US        |   4279485 | NS      | $140709466.80  | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Centene Corp                                      | CENTENE CORP                                     | CUSIP: 15135B101<br>LEI: 549300Z7JJ4TQSQGT333 | Long             | EC               | CORP              | US        |   1363754 | NS      | $73219952.26   | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| CG oncology Inc                                   | CG ONCOLOGY INC                                  | CUSIP: 156944100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2589248 | NS      | $172806411.52  | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Crinetics Pharmaceuticals Inc                     | CRINETICS PHARMA                                 | CUSIP: 22663K107<br>LEI: 549300Q1CNFXK5P31D28 | Long             | EC               | CORP              | US        |   3494255 | NS      | $135507208.90  | 0.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics Inc                                  | CYTOKINETICS INC                                 | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |   3482614 | NS      | $222782817.58  | 0.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                                      | DANAHER CORP                                     | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |   4836473 | NS      | $865486843.35  | 2.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                                        | DEXCOM                                           | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |   6365180 | NS      | $379046469.00  | 1.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Dianthus Therapeutics Inc                         | DIANTHUS THERAPE                                 | CUSIP: 252828108<br>LEI: 549300Z3N6ODPCOFC890 | Long             | EC               | CORP              | US        |   1244555 | NS      | $109271929.00  | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corp                         | EDWARDS LIFE                                     | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |  14158652 | NS      | $1182247442.00 | 3.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Encompass Health Corp                             | ENCOMPASS HEALTH                                 | CUSIP: 29261A100<br>LEI: 549300FVRPM9DRQZRG64 | Long             | EC               | CORP              | US        |   1600016 | NS      | $160001600.00  | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |
| HCA Healthcare Inc                                | HCA HEALTHCARE I                                 | CUSIP: 40412C101<br>LEI: 529900PH4ZGUH2MNEU89 | Long             | EC               | CORP              | US        |   1203410 | NS      | $522821474.50  | 1.42%             |  |  |  | No            |                  1 | On Loan: No      |
| HeartFlow Inc                                     | HEARTFLOW INC                                    | CUSIP: 42238D107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   5663321 | NS      | $168540432.96  | 0.46%             |  |  |  | No            |                  1 | On Loan: —       |
| Immunome Inc                                      | IMMUNOME INC                                     | CUSIP: 45257U108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2776580 | NS      | $63694745.20   | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                                       | INCYTE CORP                                      | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |   2365620 | NS      | $225372617.40  | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Inspire Medical Systems Inc                       | INSPIRE MEDICAL                                  | CUSIP: 457730109<br>LEI: 549300XQQCQ7HCJKTW25 | Long             | EC               | CORP              | US        |   2093826 | NS      | $117547391.64  | 0.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Genmab A/S                                        | GENMAB A/S                                       | CUSIP: N/A<br>LEI: 529900MTJPDPE4MHJ122       | Long             | EC               | CORP              | DK        |   1345944 | NS      | $356374265.00  | 0.97%             |  |  |  | No            |                  2 | On Loan: No      |
| Intuitive Surgical Inc                            | INTUITIVE SURGIC                                 | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |   2186666 | NS      | $1000640228.26 | 2.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals Inc                         | IONIS PHARMACEUT                                 | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |   3803181 | NS      | $284325811.56  | 0.77%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                                 | JOHNSON&JOHNSON                                  | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |   5527324 | NS      | $1270455421.40 | 3.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Kailera Therapeutics Inc                          | KAILERA THERAPEU                                 | CUSIP: 482931102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2127264 | NS      | $53181600.00   | 0.14%             |  |  |  | No            |                  1 | On Loan: —       |
| Kymera Therapeutics Inc                           | KYMERA THERAPEUT                                 | CUSIP: 501575104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1796469 | NS      | $145639741.83  | 0.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                                    | ELI LILLY & CO                                   | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |   3582833 | NS      | $3348515721.80 | 9.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Madrigal Pharmaceuticals Inc                      | MADRIGAL PHARMAC                                 | CUSIP: 558868105<br>LEI: 549300CHIMT2EUSNJB60 | Long             | EC               | CORP              | US        |    408918 | NS      | $211570084.02  | 0.57%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                                            | UCB SA                                           | CUSIP: B93562120<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |   2355442 | NS      | $641366325.21  | 1.74%             |  |  |  | No            |                  2 | On Loan: No      |
| Merck & Co Inc                                    | MERCK & CO                                       | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |  18279775 | NS      | $1995785834.50 | 5.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Mineralys Therapeutics Inc                        | MINERALYS THERAP                                 | CUSIP: 603170101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1858489 | NS      | $49528731.85   | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Moderna Inc                                       | MODERNA INC                                      | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |   1995366 | NS      | $91667114.04   | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Chugai Pharmaceutical Co Ltd                      | CHUGAI PHARMA CO                                 | CUSIP: N/A<br>LEI: 529900T9LAII161DCN95       | Long             | EC               | CORP              | JP        |   8606142 | NS      | $458960041.70  | 1.25%             |  |  |  | No            |                  2 | On Loan: No      |
| Eisai Co Ltd                                      | EISAI CO LTD                                     | CUSIP: N/A<br>LEI: 353800HDEE0ZYEX4QV91       | Long             | EC               | CORP              | JP        |   7339417 | NS      | $219686604.13  | 0.60%             |  |  |  | No            |                  2 | On Loan: No      |
| Natera Inc                                        | NATERA INC                                       | CUSIP: 632307104<br>LEI: 529900CQ3OZ0A0VYVU59 | Long             | EC               | CORP              | US        |    470036 | NS      | $96902621.76   | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvalent Inc                                      | NUVALENT INC-A                                   | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    873258 | NS      | $87570312.24   | 0.24%             |  |  |  | No            |                  1 | On Loan: No      |
| Shandong Weigao Group Medical Polymer Co Ltd      | SHANDONG WEIG-H                                  | CUSIP: N/A<br>LEI: 5299005WQUU15JQU8S60       | Long             | EC               | CORP              | HK        |  77092000 | NS      | $33976563.02   | 0.09%             |  |  |  | No            |                  2 | On Loan: No      |
| Shionogi & Co Ltd                                 | SHIONOGI & CO                                    | CUSIP: N/A<br>LEI: 35380049VXDTHZI3DY35       | Long             | EC               | CORP              | JP        |  20439649 | NS      | $412940923.81  | 1.12%             |  |  |  | No            |                  2 | On Loan: No      |
| Option Care Health Inc                            | OPTION CARE HEAL                                 | CUSIP: 68404L201<br>LEI: 549300DI3Q5ACSYJRI17 | Long             | EC               | CORP              | US        |   6323420 | NS      | $128555128.60  | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| PTC Therapeutics Inc                              | PTC THERAPEUTICS                                 | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |   2038232 | NS      | $132607373.92  | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                                       | NOVARTIS AG-REG                                  | CUSIP: H5820Q150<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |   4043167 | NS      | $597538313.30  | 1.62%             |  |  |  | No            |                  2 | On Loan: No      |
| Protagonist Therapeutics Inc                      | PROTAGONIST THER                                 | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1380445 | NS      | $136622641.65  | 0.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc                     | REGENERON PHARM                                  | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |    931886 | NS      | $658899315.16  | 1.79%             |  |  |  | No            |                  1 | On Loan: No      |
| REVOLUTION Medicines Inc                          | REVOLUTION MEDIC                                 | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |   1838404 | NS      | $264950784.48  | 0.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Scholar Rock Holding Corp                         | SCHOLAR ROCK HOL                                 | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |   3466533 | NS      | $161575103.13  | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Stoke Therapeutics Inc                            | STOKE THERAPEUTI                                 | CUSIP: 86150R107<br>LEI: 549300RD25SS2DIJHJ67 | Long             | EC               | CORP              | US        |   1652492 | NS      | $54069538.24   | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp                                      | STRYKER CORP                                     | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |    970510 | NS      | $305836816.30  | 0.83%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc                      | THERMO FISHER                                    | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |    745695 | NS      | $357158077.20  | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| United Therapeutics Corp                          | UNITED THERAPEUT                                 | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |    822896 | NS      | $470161629.60  | 1.28%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc                            | UNITEDHEALTH GRP                                 | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |   3895307 | NS      | $1443133337.36 | 3.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Vaxcyte Inc                                       | VAXCYTE INC                                      | CUSIP: 92243G108<br>LEI: 254900M7NMHTGASX8D95 | Long             | EC               | CORP              | US        |   2667349 | NS      | $152679056.76  | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc                        | VERTEX PHARM                                     | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |   1801919 | NS      | $770104142.22  | 2.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Xenon Pharmaceuticals Inc                         | XENON PHARMACEUT                                 | CUSIP: 98420N105<br>LEI: 549300XV44Q9Z1MIPQ03 | Long             | EC               | CORP              | US        |   2676154 | NS      | $149971670.16  | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| M3 Inc                                            | M3 INC                                           | CUSIP: J4697J108<br>LEI: 3538001UOKRWIODYM055 | Long             | EC               | CORP              | JP        |   9451653 | NS      | $91042571.94   | 0.25%             |  |  |  | No            |                  2 | On Loan: No      |
| Daiichi Sankyo Co Ltd                             | DAIICHI SANKYO                                   | CUSIP: N/A<br>LEI: 353800XGIU2IHQGC9504       | Long             | EC               | CORP              | JP        |  22675166 | NS      | $368337295.77  | 1.00%             |  |  |  | No            |                  2 | On Loan: No      |
| Otsuka Holdings Co Ltd                            | OTSUKA HOLDINGS                                  | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | JP        |   6207200 | NS      | $452394129.33  | 1.23%             |  |  |  | No            |                  2 | On Loan: No      |
| Immunocore Holdings PLC                           | IMMUNOCORE HOLDI                                 | CUSIP: N/A<br>LEI: 213800IUE3DFS84BVN18       | Long             | EC               | CORP              | US        |   4246274 | NS      | $118513507.34  | 0.32%             |  |  |  | No            |                  1 | On Loan: —       |
| Jiangsu Hengrui Pharmaceuticals Co Ltd            | JIANGSU HENGRU-H                                 | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | HK        |   9939973 | NS      | $82882299.51   | 0.22%             |  |  |  | No            |                  2 | On Loan: No      |
| GSK PLC                                           | GSK PLC                                          | CUSIP: N/A<br>LEI: 5493000HZTVUYLO1D793       | Long             | EC               | CORP              | GB        |  44002585 | NS      | $1153636373.67 | 3.13%             |  |  |  | No            |                  2 | On Loan: No      |
| Argenx SE                                         | ARGENX SE                                        | CUSIP: N/A<br>LEI: 7245009C5FZE6G9ODQ71       | Long             | EC               | CORP              | BE        |   1036146 | NS      | $812574396.64  | 2.20%             |  |  |  | No            |                  2 | On Loan: No      |
| Novo Nordisk A/S                                  | NOVO NORDISK-B                                   | CUSIP: N/A<br>LEI: 549300DAQ1CVT6CXN342       | Long             | EC               | CORP              | DK        |   4131421 | NS      | $175733846.98  | 0.48%             |  |  |  | No            |                  2 | On Loan: No      |
| Zai Lab Ltd                                       | ZAI LAB LTD                                      | CUSIP: N/A<br>LEI: 549300P2UYQ9U5LY1T58       | Long             | EC               | CORP              | HK        |  36431700 | NS      | $78191140.18   | 0.21%             |  |  |  | No            |                  2 | On Loan: No      |
| GenFleet Therapeutics Shanghai Inc                | GENFLEET THERA-H                                 | CUSIP: N/A<br>LEI: 836800OP0710UUAGDU40       | Long             | EC               | CORP              | HK        |  18491938 | NS      | $102852980.76  | 0.28%             |  |  |  | No            |                  2 | On Loan: No      |
| Structure Therapeutics Inc                        | STRUCTURE THERAP                                 | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |   2909218 | NS      | $120587086.10  | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Galderma Group AG                                 | GALDERMA GROUP A                                 | CUSIP: N/A<br>LEI: 89450001OK6O8ELQ4584       | Long             | EC               | CORP              | CH        |   2228631 | NS      | $467551954.78  | 1.27%             |  |  |  | No            |                  2 | On Loan: No      |
| Duality Biotherapeutics Inc                       | DUALITY BIOTHERA                                 | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | HK        |   2771377 | NS      | $98896474.13   | 0.27%             |  |  |  | No            |                  2 | On Loan: No      |
| Roche Holding AG                                  | ROCHE HOLDING AG-GENUSSCHEIN - PART.CERTIFICATES | CUSIP: N/A<br>LEI: 549300U41AUUVOAAOB37       | Long             | EC               | CORP              | CH        |   1122465 | NS      | $457404307.93  | 1.24%             |  |  |  | No            |                  2 | On Loan: No      |
| QIAGEN NV                                         | QIAGEN NV                                        | CUSIP: N/A<br>LEI: 54930036WK3GMCN17Z57       | Long             | EC               | CORP              | US        |   6514443 | NS      | $225269438.94  | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S                               | ASCENDIS PHARMA                                  | CUSIP: N/A<br>LEI: 549300B66JN3W3J8GH73       | Long             | EC               | CORP              | US        |   1049942 | NS      | $240835695.96  | 0.65%             |  |  |  | No            |                  1 | On Loan: No      |
| ICON PLC                                          | ICON PLC                                         | CUSIP: G4705A100<br>LEI: 6354008SRQGEMC4XFI67 | Long             | EC               | CORP              | US        |   1538110 | NS      | $182004556.30  | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                                     | MEDTRONIC PLC                                    | CUSIP: G5960L103<br>LEI: 549300GX3ZBSQWUXY261 | Long             | EC               | CORP              | US        |   4228128 | NS      | $342351524.16  | 0.93%             |  |  |  | No            |                  1 | On Loan: No      |
| STERIS PLC                                        | STERIS PLC                                       | CUSIP: G8473T100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1092821 | NS      | $237011018.48  | 0.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Newamsterdam Pharma Co NV                         | NEWAMSTERDAM PHA                                 | CUSIP: N/A<br>LEI: 984500B6549TF6E14D36       | Long             | EC               | CORP              | US        |   3425823 | NS      | $97841504.88   | 0.27%             |  |  |  | No            |                  1 | On Loan: —       |
| Vanguard Cmt Funds-Vanguard Market Liquidity Fund | Vanguard Market Liquidity Fund                   | CUSIP: N/A<br>LEI: 1I6HV0TLSTR3A4XQ6L78       | Long             | STIV             | CORP              | US        |    300351 | NS      | $30032070.39   | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| JP Morgan Securities LLC                          | JPM TRIPARTY TREAS FICC                          | CUSIP: N/A<br>LEI: ZBUT11V806EZRVTWT807       | Long             | RA               | CORP              | US        |  29000000 | PA      | $29000000.00   | 0.08%             |  |  |  | No            |                  2 | On Loan: No      |
| HSBC Bank USA                                     | HSBC TRIPARTY MTGE                               | CUSIP: N/A<br>LEI: CYYGQCGNHMHPSMRL3R97       | Long             | RA               | CORP              | US        |   9400000 | PA      | $9400000.00    | 0.03%             |  |  |  | No            |                  2 | On Loan: No      |
| Nomura Securities International, Inc.             | NOM TSY FICC                                     | CUSIP: N/A<br>LEI: OXTKY6Q8X53C9ILVV871       | Long             | RA               | CORP              | US        |  39000000 | PA      | $39000000.00   | 0.11%             |  |  |  | No            |                  2 | On Loan: No      |
| Bank of America Securities, LLC                   | BK AMER TSY FICC                                 | CUSIP: N/A<br>LEI: 8NAV47T0Y26Q87Y0QP81       | Long             | RA               | CORP              | US        |  39000000 | PA      | $39000000.00   | 0.11%             |  |  |  | No            |                  2 | On Loan: No      |
| Natixis SA                                        | NATIXIS TRIPARTY TR                              | CUSIP: N/A<br>LEI: KX1WK48MPD4Y2NCUIZ63       | Long             | RA               | CORP              | US        |  17300000 | PA      | $17300000.00   | 0.05%             |  |  |  | No            |                  2 | On Loan: No      |
| Bank of America Securities, LLC                   | BK AMER MTG FICC                                 | CUSIP: N/A<br>LEI: 8NAV47T0Y26Q87Y0QP81       | Long             | RA               | CORP              | US        |  25000000 | PA      | $25000000.00   | 0.07%             |  |  |  | No            |                  2 | On Loan: No      |
| Nomura Securities International, Inc.             | NOMURA TREAS TRIPARTY                            | CUSIP: N/A<br>LEI: OXTKY6Q8X53C9ILVV871       | Long             | RA               | CORP              | US        |  25000000 | PA      | $25000000.00   | 0.07%             |  |  |  | No            |                  2 | On Loan: No      |
| BNP Paribas Securities Corp.                      | PARIB TRIPARTY TREASURY                          | CUSIP: N/A<br>LEI: 2J5703FH5U5M97R1I237       | Long             | RA               | CORP              | US        |  30000000 | PA      | $30000000.00   | 0.08%             |  |  |  | No            |                  2 | On Loan: No      |
| BNP Paribas Securities Corp.                      | PARIB TRIPARTY MORTGAGE                          | CUSIP: N/A<br>LEI: 2J5703FH5U5M97R1I237       | Long             | RA               | CORP              | US        |  34200000 | PA      | $34200000.00   | 0.09%             |  |  |  | No            |                  2 | On Loan: No      |
| HSBC Bank USA                                     | HSBC TRIPARTY TREAS                              | CUSIP: N/A<br>LEI: CYYGQCGNHMHPSMRL3R97       | Long             | RA               | CORP              | US        |  80500000 | PA      | $80500000.00   | 0.22%             |  |  |  | No            |                  2 | On Loan: No      |
| Barclays Capital Inc.                             | BZW TRIPARTY TREASURY                            | CUSIP: N/A<br>LEI: AC28XWWI3WIBK2824319       | Long             | RA               | CORP              | US        |  37200000 | PA      | $37200000.00   | 0.10%             |  |  |  | No            |                  2 | On Loan: No      |
| Credit Agricole                                   | CREDIT AGRICOLE TRIPARTY TSY                     | CUSIP: N/A<br>LEI: 969500TJ5KRTCJQWXH05       | Long             | RA               | CORP              | US        |  21500000 | PA      | $21500000.00   | 0.06%             |  |  |  | No            |                  2 | On Loan: No      |
| Bank of Nova Scotia                               | SCOTIA TRIPARTY TREASURY                         | CUSIP: N/A<br>LEI: L3I9ZG2KFGXZ61BMYR72       | Long             | RA               | CORP              | US        |  34300000 | PA      | $34300000.00   | 0.09%             |  |  |  | No            |                  2 | On Loan: No      |
| Bank of America Securities, LLC                   | BOA-MTG TRIPARTY REPO                            | CUSIP: N/A<br>LEI: 8NAV47T0Y26Q87Y0QP81       | Long             | RA               | CORP              | US        |  31100000 | PA      | $31100000.00   | 0.08%             |  |  |  | No            |                  2 | On Loan: No      |

### Signature

**Date Signed:** 2026-06-25

**Name of Applicant:** VANGUARD SPECIALIZED FUNDS

**Signature:** My Trieu-Gatt

**Name of Signer:** My Trieu-Gatt

**Title:** Treasurer